相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。506PTPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
A Drilon et al.
ANNALS OF ONCOLOGY (2019)
LBA93Registrational results of LOXO-292 in patients with RET-altered thyroid cancers
L Wirth et al.
ANNALS OF ONCOLOGY (2019)
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Huiying Han et al.
CANCER CELL (2019)
Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
A. Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alexander Drilon et al.
CANCER DISCOVERY (2019)
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer
Roberto Ferrara et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Franz X. Schaub et al.
CELL SYSTEMS (2018)
RET rearrangements are actionable alterations in breast cancer
Bhavna S. Paratala et al.
NATURE COMMUNICATIONS (2018)
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Gang G. Li et al.
CLINICAL CANCER RESEARCH (2017)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Oliver Gautschi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub
Tirtha Kamal Das et al.
CELL REPORTS (2017)
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh et al.
LANCET RESPIRATORY MEDICINE (2017)
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
Francesco Facchinetti et al.
CANCER TREATMENT REVIEWS (2017)
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice
M. Caccese et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer
Dong-Wook Kim et al.
GENES & DEVELOPMENT (2016)
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Alexander Drilon et al.
LANCET ONCOLOGY (2016)
Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results
Mumtahena Rahman et al.
BIOINFORMATICS (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Identification and characterization of RET fusions in advanced colorectal cancer
Anne-France Le Rolle et al.
ONCOTARGET (2015)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions
Yoshiyuki Suehara et al.
CLINICAL CANCER RESEARCH (2012)
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
Young Seok Ju et al.
GENOME RESEARCH (2012)
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson et al.
NATURE MEDICINE (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
Oncogene-Mediated Human Lung Epithelial Cell Transformation Produces Adenocarcinoma Phenotypes In Vivo
Ken Sasai et al.
CANCER RESEARCH (2011)
Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
Juliann Chmielecki et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Targeting RET Receptor Tyrosine Kinase Activation in Cancer
John E. Phay et al.
CLINICAL CANCER RESEARCH (2010)
Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis
Benson C. Lu et al.
NATURE GENETICS (2009)
Multiple oncogenic changes (K-RASV12, p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells
M Sato et al.
CANCER RESEARCH (2006)
RET tyrosine kinase signaling in development and cancer
E Arighi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Tumor dormancy and MYC inactivation: Pushing cancer to the brink of normalcy
CM Shachaf et al.
CANCER RESEARCH (2005)
Sustained loss of a neoplastic phenotype by brief inactivation of MYC
M Jain et al.
SCIENCE (2002)
The RET proto-oncogene in human cancers
SM Jhiang
ONCOGENE (2000)
分享论文
